Status:
WITHDRAWN
Phosphatidylcholine Supplementation in Infants
Lead Sponsor:
University of Colorado, Denver
Conditions:
Schizophrenia
Diminished P50 Sensory Gating
Eligibility:
All Genders
1-7 years
Phase:
PHASE1
PHASE2
Brief Summary
Sensory gating is defined as the automatic process of inhibiting brain response to repeated auditory sounds. Infants who brains respond similarly to two identical sounds presented about 1/2 second apa...
Eligibility Criteria
Inclusion
- Healthy infant has an age (adjusted for gestational age at birth) of 1-7 weeks
- Diminished P50 sensory gating (ratio greater than or equal to 0.50)
Exclusion
- No maternal reported tobacco use for greater than 1 year and no current tobacco use (as measured by urine cotinine levels)
- Trimethylaminuria, renal disease, liver disease, known chromosomal abnormality, chronic neurological disorder, premature birth, prenatal exposure to exogenous steroid use
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01905605
Start Date
September 1 2013
End Date
January 1 2017
Last Update
September 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver
Aurora, Colorado, United States, 80045